Buerger's disease: What has the last decade taught us?

European Journal of Internal Medicine

Volumn 17, Issue 4, 2006, Pages 227-234

  Kroger K ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Buerger's disease; Peripheral arterial disease; Thrombangiitis obliterans

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; ILOPROST; NITROPRUSSIDE SODIUM; PLASMID DNA; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN; VASODILATOR AGENT;

AMPUTATION; ANGIOGRAPHY; ARTERY DISEASE; B LYMPHOCYTE; BUERGER DISEASE; CELL ACTIVATION; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; DENDRITIC CELL; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; ENDARTERITIS; ENVIRONMENTAL FACTOR; HUMAN; HUMORAL IMMUNITY; INTIMA; MACROPHAGE ACTIVATION; PAIN; REVASCULARIZATION; REVIEW; SMOKING; SMOKING CESSATION; SURGICAL TECHNIQUE; SYMPATHECTOMY; T LYMPHOCYTE; TREATMENT OUTCOME; WOUND CARE;

EID: 33744530332     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2005.11.020     Document Type: Review

References (75)

1. Adar R. Letter: Buerger's disease-the need for diagnostic criteria. Surgery 76 (1974) 848
2. Papa M.Z., Rabi I., and Adar R. A point scoring system for the clinical diagnosis of Buerger's disease. Eur J Vasc Endovasc Surg 11 (1996) 335-339
3. Shionoya S. Diagnostic criteria of Buerger's disease. Int J Cardiol 66 Suppl 1 (1998) S243-S245
4. Mills Sr. J.L. Buerger's disease in the 21st century: diagnosis, clinical features, and therapy. Semin Vasc Surg 16 (2003) 179-189
5. Sasaki S., Sakuma M., and Yasuda K. Current status of thromboangiitis obliterans (Buerger's disease) in Japan. Int J Cardiol 75 Suppl 1 (2000) S175-S181
6. Fujii Y., Ohmura Y., Takeuchi R., Morimoto S., Uchida H., Hayashi K., et al. Buerger's disease in a middle-aged woman with diabetes mellitus. A case report. Angiology 47 (1996) 97-102
7. Takami S., Kubo M., Yamashita S., Kameda-Takemura K., Kawasaki T., Kanbayashi J., et al. High levels of serum lipoprotein(a) in patients with ischemic heart disease with normal coronary angiogram and thromboangiitis obliterans. Atherosclerosis 112 (1995) 253-260
8. Godoy de J.M., Braile D.M., and Godoy M.F. Buerger's disease and anticardiolipin antibodies: a worse prognosis?. Clin Appl Thromb Hemost 8 (2002) 85-86
9. Adar R., Papa M.Z., and Schneiderman J. Thromboangiitis obliterans: an old disease in need of a new look. Int J Cardiol 75 Suppl 1 (Aug 31 2000) S167-S170
10. Scharf G.M., van Wyk F.A., Cloete G.N., and Rautenbach B.K. Buerger's disease or Buerger's syndrome? An analysis of 12 cases. S Afr Med J 70 (1986) 803-805
11. Tanaka K. Pathology and pathogenesis of Buerger's disease. Int J Cardiol 66 Suppl 1 (Oct 1 1998) S237-S242
12. Makita S., Nakamura M., Murakami H., Komoda K., Kawazoe K., and Hiramori K. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans. Circulation 94 9 Suppl (1996) II211-II215
13. Halacheva K., Gulubova M.V., Manolova I., and Petkov D. Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochem 104 (2002) 177-184
14. Kim E.J., Cho B.S., Lee T.S., Kim S.J., and Seo J.W. Morphologic change of the internal elastic lamina in Buerger's disease. J Korean Med Sci 15 (2000) 44-48
15. Kurata A., Machinami R., Schulz A., Fukayama M., and Franke F.E. Different immunophenotypes in Buerger's disease. Pathol Int 53 (2003) 608-615
16. Lee T., Seo J.W., Sumpio B.E., and Kim S.J. Immunobiologic analysis of arterial tissue in Buerger's disease. Eur J Vasc Endovasc Surg 25 (2003) 451-457
17. Kobayashi M., Ito M., Nakagawa A., Nishikimi N., and Nimura Y. Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease. J Vasc Surg 29 (1999) 451-458
18. Lamprecht R. Beitrag zur Pathogenese der Thrombangitis obliterans. Vasa suppl 20 (1987) 212-215
19. Roncon-Albuquerque R., Serrao P., Vale-Pereira R., Costa-Lima J., and Roncon-Albuquerque Jr. R. Plasma catecholamines in Buerger's disease: effects of cigarette smoking and surgical sympathectomy. Eur J Vasc Endovasc Surg 24 (2002) 338-343
20. Kröger K., Kreuzfelder E., Moser C., Santosa F., Buss C., and Grosse-Wilde H. Thrombangitis obliterans: leucocyte subpopulations and circulating immune complexes. Vasa 30 (2001) 189-194
21. Maslowski L., McBane R., Alexewicz P., and Wysokinski W.E. Antiphospholipid antibodies in thromboangiitis obliterans. Vasc Med 7 (2002) 259-264
22. Cnotliwy M., Gutowski P., Szumilowicz H., Kucharska E., Jastrzebska M., and Ostanek L. Anticardiolipin antibodies in patients with Buerger's disease. Wiad Lek 52 (1999) 332-336
23. Halacheva K.S., Manolova I.M., Petkov D.P., and Andreev A.P. Study of anti-neutrophil cytoplasmic antibodies in patients with thromboangiitis obliterans. Scand J Immunol 48 (1998) 544-550
24. Iwai T., Inoue Y., Umeda M., Huang Y., Kurihara N., Koike M., et al. Oral bacteria in the occluded arteries of patients with Buerger disease. J Vasc Surg 42 (2005) 107-115
25. Caramaschi P., Biasi D., Volpe A., Carletto A., and Bambara L.M. Aspects of thrombophilia in Buerger's disease. Recenti Prog Med 91 (2000) 436-440
26. Avcu F., Akar E., Demirkilic U., Yilmaz E., Akar N., and Yalcin A. The role of prothrombotic mutations in patients with Buerger's disease. Thromb Res 100 (2000) 143-147
27. Bozkurt A.K., Besirli K., Koksal C., Sirin G., Yuceyar L., Tuzun H., et al. Surgical treatment of Buerger's disease. Vascular 12 (2004) 192-197
28. Papa M., Bass A., Adar R., Halperin Z., Schneiderman J., Becker C.G., et al. Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex. Surgery 111 (1992) 527-531
29. Joyce J.W. Buerger's disease (thromboangiitis obliterans). Rheum Dis Clin North Am 16 (1990) 463-470
30. Wysokinski W.E., Kwiatkowska W., Sapian-Raczkowska B., Czarnacki M., Doskocz R., and Kowal-Gierczak B. Sustained classic clinical spectrum of thromboangiitis obliterans. Angiology 51 (2000) 141-150
31. Makin A., Silverman S., and Lip G.Y. Ethnic differences in peripheral vascular disease. Int J Clin Pract 56 (2002) 605-608
32. Fleshman K. Buerger's disease in Nepal. Trop Doct 28 (1998) 203-206
33. Matsushita M., Nishikimi N., Sakurai T., and Nimura Y. Decrease in prevalence of Buerger's disease in Japan. Surgery 124 (1998) 498-502
34. Lie J.T. The rise and fall and resurgence of thromboangiitis obliterans. Acta Pathol Jpn 39 (1989) 153-158
35. Olin J.W., Young J.R., Graor R.A., Ruschhaupt W.F., and Bartholomew J.R. The changing clinical spectrum of thromboangiitis obliterans. Circulation 82 5 Suppl (1990) IV3-IV8
36. Sasaki S., Sakuma M., Kunihara T., and Yasuda K. Distribution of arterial involvement in thromboangiitis obliterans: results of a study conducted by the intractable vasculitis syndromes research group in Japan. Surg Today 30 (2000) 600-605
37. Shigematsu H., and Shigematsu K. Factors affecting the long-term outcome of Buerger's disease. Int Angiol 18 (1999) 58-64
38. Jimenez-Paredes C.A., Canas-Davila C.A., Sanchez A., Restrepo J.F., Pena M., and Iglesias-Gamarra A. Buerger's disease at the 'San Juan De Dios' Hospital, Santa Fe De Bogota, Colombia. Int J Cardiol 66 Suppl 1 (1998) 267-272
39. Lau H., and Cheng S.W. Buerger's disease in Hong Kong: a review of 89 cases. Aust N Z J Surg 67 (1997) 264-269
40. Borner C., and Heidrich H. Long-term follow-up of thromboangiitis obliterans. Vasa 27 (1998) 80-86
41. Matchev S., Petrov V., Batchvarova V., Maljakova A., and Doneva S. Transcranial Doppler velocities in patients with thromboangiitis obliterans. Angiology 48 (1997) 535-544
42. Jaff M.R. Thromboangiitis Obliterans (Buerger's disease). Curr Treat Options Cardiovasc Med 2 (2000) 205-212
43. Fiessinger J.N., and Schafer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO study. Lancet 335 8689 (1990) 555-557
44. Oral iloprost in the treatment of thromboangiitis obliterans: a double-blind, randomised, placebo-controlled trial. The European TAO study group. Eur J Vasc Endovasc Surg 15 (1998) 300-307
45. Han Z.C., and Yang C. Peripheral blood stem cell transplantation in the treatment of thromboangitis Obliterans. Zhonghua Yi Xue Za Zhi 84 (2004) 1334
46. Miyamoto M., Yasutake M., Takano H., Takagi H., Takagi G., Mizuno H., et al. Therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease using assessment of neovascularization by 99mTc-tetrofosmin (TF) perfusion scintigraphy. Cell Transplant 13 (2004) 429-437
47. Taguchi A., Ohtani M., Soma T., Watanabe M., and Kinosita N. Therapeutic angiogenesis by autologous bone-marrow transplantation in a general hospital setting. Eur J Vasc Endovasc Surg 25 (2003) 276-278
48. Kim H.J., Jang S.Y., Park J.I., Byun J., Kim D.I., Do Y.S., et al. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp Mol Med 36 (2004) 336-344
49. Morishita R., Aoki M., Hashiya N., Makino H., Yamasaki K., Azuma J., et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 44 (2004) 203-209
50. Isner J.M., Walsh K., Symes J., Pieczek A., Takeshita S., Lowry J., et al. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum Gene Ther 20 7 (1996) 959-988
51. Naito A.T., Minamino T., Tateno K., Nagai T., and Komuro I. Steroid-responsive thromboangiitis obliterans. Lancet 364 9439 (2004) 1098
52. Gur'eva M.S., Baranov A.A., Bagrakova S.V., and Kurdiukov A.A. Pulse-therapy with glucocorticoids and cyclophosphamide in the treatment of thromboangiitis obliterans. Klin Med 81 (2003) 53-57
53. Saha K., Chabra N., and Gulati S.M. Treatment of patients with thromboangiitis obliterans with cyclophosphamide. Angiology 52 (2001) 399-407
54. Eisenberg R., and Looney R.J. The therapeutic potential of anti-CD20 "What do B-cells do?". Clin Immunol (Sep 15 2005) [Electronic publication ahead of print]
55. Hodgson T.J., Gaines P.A., and Beard J.D. Thrombolysis and angioplasty for acute lower limb ischemia in Buerger's disease. Cardiovasc Intervent Radiol 17 (1994) 333-335
56. Kubota Y., Kichikawa K., Uchida H., Nishimine K., Hirohashi R., and Ohishi H. Superselective urokinase infusion therapy for dorsalis pedis artery occlusion in Buerger's disease. Cardiovasc Intervent Radiol 20 (1997) 380-382
57. Gordon A., Zechmeister K., and Collin J. The role of sympathectomy in current surgical practice. Eur J Vasc Surg 8 (1994) 129-137
58. Bozkurt A.K., Koksal C., and Ercan M. The altered hemorheologic parameters in thromboangiitis obliterans: a new insight. Clin Appl Thromb Hemost 10 (2004) 45-50
59. Nakajima N. The change in concept and surgical treatment on Buerger's disease-personal experience and review. Int J Cardiol 66 Suppl 1 (1998) S273-S280
60. Singh K., and Sood S. Autonomic functions in Buerger's disease. Indian J Physiol Pharmacol 45 (2001) 470-474
61. Swigris J.J., Olin J.W., and Mekhail N.A. Implantable spinal cord stimulator to treat the ischemic manifestations of thromboangiitis obliterans. J Vasc Surg 29 (1999) 928-935
62. Galley D., Rettori R., Boccalon H., Medvedowsky A., Lefebvre J.M., Sellier F., et al. Electric stimulation of the spinal cord in arterial diseases of the legs. A multicenter study of 244 patients. J Mal Vasc 17 (1992) 208-213
63. Bozkurt A.K., Tuzun H., Sayin A.G., Karaozbek Y., Koksal C., and Ozer M. The role of polytetrafluoroethylene graft material in Buerger's disease. Int J Angiol 7 (1998) 188-190
64. Izumi Y., Sasajima T., Inaba M., Morimoto N., Goh K., and Kubo Y. Results of arterial reconstruction in Buerger's disease. Nippon Geka Gakkai Zasshi 94 (1993) 751-754
65. Sasajima T., Kubo Y., Inaba M., Goh K., and Azuma N. Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience. Eur J Vasc Endovasc Surg 13 (1997) 186-192
66. Dilege S., Aksoy M., Kayabali M., Genc F.A., Senturk M., and Baktiroglu S. Vascular reconstruction in Buerger's disease: is it feasible?. Surg Today 32 (2002) 1042-1047
67. Ohta T., Ishioashi H., Hosaka M., and Sugimoto I. Clinical and social consequences of Buerger disease. J Vasc Surg 39 (2004) 176-180
68. Nishikimi N. Fate of limbs with failed vascular reconstruction in Buerger's disease patients. Int J Cardiol 75 Suppl 1 (Aug 31 2000) S183-S518
69. Kosenkov A.N., Chalbanova T.M., Abramov IuA., Fedoseeva A.K., and Dzhabbarov V.V. Evaluation of results of surgical treatment of obliterating thrombangiitis in patients living in the North Arctic. Khirurgiia 8 (2004) 32-36
70. Talwar S., Jain S., Porwal R., Laddha B.L., and Prasad P. Free versus pedicled omental grafts for limb salvage in Buerger's disease. Aust N Z J Surg 68 (1998) 38-40
71. Talwar S., and Choudhary S.K. Omentopexy for limb salvage in Buerger's disease: indications, technique and results. J Postgrad Med 47 (2001) 137-142
72. Khazanchi R.K., Nanda V., Kumar R., Garg P., Guleria S., and Bal S. Omentum autotransplantation in thromboangiitis obliterans: report of three cases. Surg Today 29 (1999) 86-90
73. Otterstad J.E., and Strom O. A patient with thromboangiitis obliterans. Tidsskr Nor Laegeforen 122 (2002) 172-173
74. Cooper L.T., Tse T.S., Mikhail M.A., McBane R.D., Stanson A.W., and Ballman K.V. Long-term survival and amputation risk in thromboangiitis obliterans. J Am Coll Cardiol 44 (2004) 2410-2411
75. Rahman M., Chowdhury A.S., Fukui T., Hira K., and Shimbo T. Association of thromboangiitis obliterans with cigarette and bidi smoking in Bangladesh: a case-control study. Int J Epidemiol 29 (2000) 266-270